New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

被引：14
|
作者：
Sonnenblick, Amir [1 ,2 ]
Fumagalli, Debora [2 ]
Azim, Hatem A., Jr. [1 ]
Sotiriou, Christos [2 ]
Piccart, Martine [1 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, BrEAST Data Ctr, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
来源：
CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 24期
关键词：
GENE-EXPRESSION; INFILTRATING LYMPHOCYTES; DISTANT RECURRENCE; TISSUE FIXATION; TRASTUZUMAB; CHEMOTHERAPY; RISK; PROGNOSIS; SURVIVAL; WOMEN;
D O I：
10.1158/1078-0432.CCR-14-1086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Awareness of breast cancer heterogeneity has strikingly increased in the past decade in parallel with the development of high-throughput molecular tests. Beyond the clear usefulness of antiestrogen treatment in luminal tumors and trastuzumab in HER2-positive tumors, breast cancer subtypes may have additional clinical and predictive roles that can be relevant to clinical practice. In this article, we discuss the significance of molecular subtypes in the systemic treatment of early-stage breast tumors smaller than 1 cm (T1a,bN0M0) and suggest new strategies for future treatment recommendations for these patients. (C) 2014 AACR.
引用
收藏
页码：6242 / 6246
页数：5
相关论文
共 50 条
  • [1] Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors
    Rakkhit, R.
    Broglio, K.
    Peintinger, F.
    Cardoso, F.
    Hanrahan, E. O.
    Litton, J. K.
    Sahin, A.
    Larsimont, D.
    Meric-Bernstam, F.
    Buchholz, T. A.
    Valero, V.
    Theriault, R. L.
    Piccart, M.
    Ravdin, P.
    Hortobagyi, G. N.
    Gonzalez-Angulo, A. M.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 98S - 98S
  • [2] Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
    Kelly, C. M.
    Pritchard, K. I.
    Trudeau, M.
    Andreopoulou, E.
    Hess, K.
    Pusztai, L.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (11) : 2387 - 2393
  • [3] Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
    Sanji Ali
    Jace Hendry
    Duc Le
    Prosanta K. Mondal
    Amer Sami
    Haji Chalchal
    Kamal Haider
    Osama Ahmed
    Ali El-Gayed
    Philip Wright
    Mehrnoosh Pauls
    Kate Johnson
    Shahid Ahmed
    [J]. Scientific Reports, 12
  • [4] Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
    Ali, Sanji
    Hendry, Jace
    Le, Duc
    Mondal, Prosanta K.
    Sami, Amer
    Chalchal, Haji
    Haider, Kamal
    Ahmed, Osama
    El-Gayed, Ali
    Wright, Philip
    Pauls, Mehrnoosh
    Johnson, Kate
    Ahmed, Shahid
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Takahashi, Yuko
    Terata, Kaori
    Kida, Kumiko
    Sagara, Yasuaki
    Ueno, Takayuki
    Anan, Keisei
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Naito, Yoichi
    Hara, Fumikata
    Shien, Tadahiko
    Iwata, Hiroji
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (03) : 473 - 483
  • [6] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
    Shinsuke Sasada
    Naoto Kondo
    Hiroya Hashimoto
    Yuko Takahashi
    Kaori Terata
    Kumiko Kida
    Yasuaki Sagara
    Takayuki Ueno
    Keisei Anan
    Akihiko Suto
    Chizuko Kanbayashi
    Mina Takahashi
    Rikiya Nakamura
    Toshiyuki Ishiba
    Michiko Tsuneizumi
    Seiichiro Nishimura
    Yoichi Naito
    Fumikata Hara
    Tadahiko Shien
    Hiroji Iwata
    [J]. Breast Cancer Research and Treatment, 2023, 202 : 473 - 483
  • [7] Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma
    Hanrahan, Emer O.
    Gonzalez-Angulo, Ana M.
    Giordano, Sharon H.
    Rouzier, Roman
    Broglio, Kristine R.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 4952 - 4960
  • [8] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
    Takahashi, Yuko
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Terata, Kaori
    Sagara, Yasuaki
    Naito, Yoichi
    Kida, Kumiko
    Ueno, Takayuki
    Anan, Keisei
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Hara, Fumikata
    Shien, Tadahiko
    Iwata, Hiroji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Clinical Features and Survival Analysis of T1mic, a, bN0M0 Breast Cancer
    Li, Junnan
    Liu, Xiaodong
    Tong, Zhongsheng
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 471 - 476
  • [10] Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study
    Hendry, J.
    Ali, S.
    Ahmed, O.
    Chalchal, H.
    El-Gayed, A.
    Haider, K.
    Iqbal, N.
    Johnson, K.
    Le, D.
    Maas, B.
    Manna, M.
    Pauls, M.
    Salim, M.
    Sami, A.
    Wright, P.
    Younis, M.
    Ahmed, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S45 - S46
12345